# Clinical Trials Data EGFR - Document 140

# Analysis of Plasma Tumor DNA in Lung Cancer Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT01930474

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer\n\* Have molecular evidence of genetic alterations in tumor sample (eg. EGFR mutations, ALK fusions)\n\* Patients must have given written informed consent\n\nExclusion Criteria:\n\n\* Patients who refuse the blood samplings",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "The non-small cell lung cancer patients who will be or have been treated with chemotherapy (including target agents)",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with an EGFR gene mutation would be eligible for this clinical trial. The inclusion criteria specifically state "\*Have molecular evidence of genetic alterations in tumor sample (eg. EGFR mutations, ALK fusions)\*". Having an EGFR mutation satisfies this requirement.